- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
Cannabinoid transporters, often referred to as anandamide membrane transporters (AMTs), uptake endocannabinoids and limit their activity at CB1, CB2 and GPR55 receptors. They facilitate endocannabinoid breakdown by internalizing the molecule.
|Cat No||Product Name / Activity|
|Anandamide uptake inhibitor; also FAAH inhibitor and CB receptor partial agonist|
|Anandamide transport inhibitor|
|Potent CB1 and TRPV1 (VR1) agonist/anandamide transport inhibitor|
|Natural cannabinoid; AMT inhibitor, GPR55 antagonist, weak CB1 antagonist, CB2 inverse agonist|
|Metabolically stable anandamide transport inhibitor|
|Novel, potent anandamide uptake inhibitor; inhibits FAAH|
|Inhibitor of anandamide uptake|
|Potent inhibitor of anandamide uptake|
|Potent anandamide transport inhibitor|
|Potent, selective anandamide transport inhibitor|
|1686||VDM 11 (in Tocrisolve™ 100)|
|Potent, selective anandamide transport inhibitor (in water-soluble emulsion)|
Cannabinoid transporters, often referred to as anandamide membrane transporters (AMTs), uptake endocannabinoids and limit their activity at CB1, CB2 and GPR55 receptors. Cannabinoid transporters facilitate endocannabinoid breakdown by internalizing the molecule and allowing access to fatty acid amide hydrolase (FAAH).
As endocannabinoids are widely distributed, it has been suggested that AMTs are also found in many different tissues, although this is as yet unverified. The cannabinoid transporter is thought to play a vital role in the endocannabinoid system, but currently little is known about it and the gene encoding this protein is uncharacterized.